<code id='06D4BC02DE'></code><style id='06D4BC02DE'></style>
    • <acronym id='06D4BC02DE'></acronym>
      <center id='06D4BC02DE'><center id='06D4BC02DE'><tfoot id='06D4BC02DE'></tfoot></center><abbr id='06D4BC02DE'><dir id='06D4BC02DE'><tfoot id='06D4BC02DE'></tfoot><noframes id='06D4BC02DE'>

    • <optgroup id='06D4BC02DE'><strike id='06D4BC02DE'><sup id='06D4BC02DE'></sup></strike><code id='06D4BC02DE'></code></optgroup>
        1. <b id='06D4BC02DE'><label id='06D4BC02DE'><select id='06D4BC02DE'><dt id='06D4BC02DE'><span id='06D4BC02DE'></span></dt></select></label></b><u id='06D4BC02DE'></u>
          <i id='06D4BC02DE'><strike id='06D4BC02DE'><tt id='06D4BC02DE'><pre id='06D4BC02DE'></pre></tt></strike></i>

          explore

          explore

          author:focus    Page View:48758
          Adobe

          Have you ever seen a mouse with a set of muscles more appropriate for a bodybuilder or comic book superhero?

          Well, 25 years ago, researchers at Johns Hopkins University made it happen. By silencing a gene responsible for producing a protein called myostatin, they directed tiny mouse bodies to grow double the amount of lean muscle they would normally, leading to mice with bulky arms, defined pectorals, and an overall more substantial body mass. They were dubbed “mighty mice.”

          advertisement

          Now, biotech startups are hoping to use those findings to create what they believe will be better weight loss medications. In the last several months, multiple companies have disclosed they are testing drugs that preserve or grow muscle while reducing fat, as shown in the updated STAT Obesity Drug Tracker. They hope that their drugs, possibly when used in conjunction with existing obesity treatments, will result in healthier weight loss.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          A letter from the executive editor: The 2023 STATUS List
          A letter from the executive editor: The 2023 STATUS List

          Aftermonthsofvigorousdeliberations,I’mthrilledtoannounceour2023STATUSList—thedefinitiverosterofleade

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Why Novartis is changing the name of its research labs

          FionaMarshall,presidentoftheNovartisresearchhubinCambridge,Mass.,speaksThursdayduringtheSTATFutureSu